Abstract
51
Helicobacter pylori is a significant gastrointestinal pathogen responsible for chronic 52 active gastritis, peptic ulcers and related gastric cancers (7). The current established treatments 53 for H. pylori infection are numerous and include triple or quadruple therapy both of which 54 utilise two antibiotics (metronidazole, amoxicillin tetracycline or clarithromycin) in addition to 55 either a proton pump inhibitor (PPI) (triple therapy) or PPI and bismuth (quadruple therapy). 56 The efficacies of these treatment strategies have been severely hampered in recent years due 57 to the rise in antibiotic resistance of H. pylori isolates and is now at the point where the current rate of eradication has dropped below 70% in many countries (8) Carbon cartridge to replace the non-volatile buffer with H 2 O in a 2.5-s wash cycle at a flow rate 137 of 1.5 mL/min. The substrate and product were co-eluted to the mass spectrometer in 4 to 8 s 138 using 70 : 30 : 0.02 = acetonitrile: water: ammonium hydroxide at a flow rate of 0.9 mL/min.
139
The chromatograph system produced baseline-resolved peaks. The eluted sample passed 140 directly into the MS ion source under negative ion mode for quantitative analysis. The other parameters for each analyte are given as supplemental data ( Table S4 ). with library compounds at 100, 66.7, 44.4, 29.6, 19.8, 13.2, 8.8, 5.9, 3.9, 2.6, 1.7 SIE averaging on molecular dynamics trajectories using SIETRAJ as described previously (34, 36, 203 37) to obtain the final binding affinity scores.
Results

205
Development of an optimized HTS assay for Pse biosynthetic enzymes 206 The Pse biosynthetic pathway is outlined in Figure 1 . The final concentrations of each H. pylori enzyme are provided as supplemental data (Table S2) .
217
In a preliminary screening of over 20,000 compounds these conditions led to a Z'-factor of 0.88 218 indicating that the assay was robust and suitable for HTS (supplemental data, Fig. S1 ).
219
Using this assay, we have completed in duplicate an HTS of a library comprising 220 approximately 100,000 small-molecule compounds in order to identify inhibitors for the 5 221 enzymes of the pathway (Fig. 2) . This screening was carried out at the compound concentration calculated. Since all the substrates and products in the Pse pathway are hydrophilic (Fig. 1) (Table S3) .
253
The HTMS assay was used for screening of 1,773 unique hits identified from the primary 254 screening. Single-concentration screening was performed at 30 μM compound concentration. tested hits (Fig. 3) compounds, with the most populated cluster reaching 40 compounds (Fig. 4) . unrelated to Pse enzymes (9 enzymes and 4 non-enzyme targets). We found that the vast majority of these multi-Pse-enzyme inhibitors were not hits against any of these unrelated 289 targets, and only 4 compounds were among the hits for 2 of these 13 unrelated targets (Table   290   S5 (Fig. 5, and supplemental data, Fig. S2, S4) . We next focused our attention on inhibitors of PseB, the first enzyme in the pathway. The 316 reasons to focus on PseB were: (1) it is the first enzyme in the pathway and hence it may lead to 317 more effective inhibition, (2) it has a solved crystal structure, and (3) it may act as a kinetic 318 bottleneck based on the optimized conditions for the pot assay (Table S2) . Hence, the 319 remaining hits (non-PseB inhibitors) were deemed less attractive at the moment. From the 320 PseB hits, we selected 20 hits from the top-50 hits and having at least 3 SD above the average 321 inhibition in the screen, and which were also present in the 6 most populated chemical clusters 322 (Fig. 4) . The rationale was to allow retrospective SAR for progressed compounds that will not 323 only inform on the importance of various substituents but also on compound selectivity and 324 possible promiscuity. This is not to say that other hits are not worth pursuing in the future and Nonetheless, these five compounds are well within the drug-likeliness ranges for the number of 332 rotatable bonds and the polar surface area, which together have been found to be a better 333 predictor of oral bioavailability than the LR5 rule of thumb (42) ( Table S7 ).
334
Following chemical clustering analysis of the top 320 confirmed hits against PseB ( Fig.   335 4), we found that these five PseB inhibitors belonged to two distinct chemical clusters but 336 nevertheless shared a related core substructure (Fig. 6) . Inhibitors CD09463 and CD23703 H. pylori PseB (Fig. 7) . However, one of the cluster-5 compounds (CD36508) appeared not to ( Fig. 6) were found to inhibit flagellin production in a dose-dependent manner. Inhibition was 379 observed at compound concentrations of 100 µM or higher (Fig. 8) . see Fig. 4 ), these clusters include analogs that inhibit more than one enzyme in the pathway.
403
Inhibiting the biosynthetic pathway simultaneously at several points can be beneficial not only solvent-exposed and makes minimal contact with the enzyme, and is not predicted to bind in all three inhibited similarly PseB from H. pylori (Fig. 7) 
